Moreover, viability assays with another GC-sensitive B-ALL cell line 697, a representative of TCF3-PBX1 fusion, indicated that the potentiating effect of SUMOi on Dex is not restricted to NALM6 cells representing the DUX4-IGH genetic subtype. This evidence concerns the gene PBX1 and precursor B-cell acute lymphoblastic leukemia.